Related Experiment Videos
Fondaparinux: an update on new study results
1Vascular Medicine, Medical Department IV, Klinikum Darmstadt, Germany. bauersachs@em.uni-frankfurt.de
European Journal of Clinical Investigation
|February 11, 2005
Summary
Fondaparinux effectively prevents and treats venous thromboembolism (VTE) across various surgical and medical settings. This selective factor Xa inhibitor demonstrates comparable or superior efficacy to existing treatments with no increased bleeding risk.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Thrombosis Research
Background:
- Fondaparinux is a selective factor Xa inhibitor.
- It is approved for thromboprophylaxis post-orthopaedic surgery.
- Recent trials explore its use in broader VTE prevention and treatment.
Purpose of the Study:
- To evaluate fondaparinux's efficacy and safety in diverse clinical scenarios.
- To compare fondaparinux with existing anticoagulants and placebo.
- To assess its role in VTE prevention and treatment.
Main Methods:
- Randomized double-blind trials (PEGASUS, ARTEMIS).
- Comparison with dalteparin, placebo, enoxaparin, and unfractionated heparin.
- Evaluation in high-risk abdominal surgery, acutely ill medical patients, DVT, and PE.
Main Results:
- Fondaparinux reduced VTE incidence in abdominal surgery (6.1% to 4.6%) and acutely ill medical patients (10.5% to 5.6%).
- No increased bleeding risk observed in these trials.
- ARTEMIS trial showed no pulmonary embolism in the fondaparinux group versus five fatal cases in placebo.
- MATISSE trials indicated non-inferior efficacy and safety compared to enoxaparin and unfractionated heparin.
Conclusions:
- Fondaparinux shows significant potential in preventing and treating venous thromboembolism.
- It offers a favorable safety profile, with no increased bleeding risk.
- Fondaparinux may simplify and improve thrombosis management in various medical and surgical contexts.